| Mendelian randomization E Birney Cold Spring Harbor perspectives in medicine, a041302, 2021 | 276 | 2021 |
| The interferon landscape along the respiratory tract impacts the severity of COVID-19 B Sposito, A Broggi, L Pandolfi, S Crotta, N Clementi, R Ferrarese, S Sisti, ... Cell 184 (19), 4953-4968. e16, 2021 | 202 | 2021 |
| Alternative methods of vaccine delivery: an overview of edible and intradermal vaccines E Criscuolo, V Caputo, RA Diotti, GA Sautto, GA Kirchenbaum, ... Journal of immunology research 2019 (1), 8303648, 2019 | 116 | 2019 |
| Naringenin is a powerful inhibitor of SARS-CoV-2 infection in vitro N Clementi, C Scagnolari, A D’Amore, F Palombi, E Criscuolo, F Frasca, ... Pharmacological research 163, 105255, 2021 | 115 | 2021 |
| Viral respiratory pathogens and lung injury N Clementi, S Ghosh, M De Santis, M Castelli, E Criscuolo, I Zanoni, ... Clinical microbiology reviews 34 (3), 10.1128/cmr. 00103-20, 2021 | 111 | 2021 |
| Fast inactivation of SARS-CoV-2 by UV-C and ozone exposure on different materials E Criscuolo, RA Diotti, R Ferrarese, C Alippi, G Viscardi, C Signorelli, ... Emerging Microbes & Infections 10 (1), 206-209, 2021 | 89 | 2021 |
| Interferon-β-1a inhibition of severe acute respiratory syndrome–coronavirus 2 in vitro when administered after virus infection N Clementi, R Ferrarese, E Criscuolo, RA Diotti, M Castelli, C Scagnolari, ... The Journal of infectious diseases 222 (5), 722-725, 2020 | 77 | 2020 |
| Bacteriophages and Their Immunological Applications against Infectious Threats C Elena, S Spadini, J Lamanna, M Ferro, R Burioni Journal of Immunology Research 2017, 13, 2017 | 77* | 2017 |
| Differential plasmacytoid dendritic cell phenotype and type I Interferon response in asymptomatic and severe COVID-19 infection M Severa, RA Diotti, MP Etna, F Rizzo, S Fiore, D Ricci, M Iannetta, ... PLoS pathogens 17 (9), e1009878, 2021 | 72 | 2021 |
| COVID-eVax, an electroporated DNA vaccine candidate encoding the SARS-CoV-2 RBD, elicits protective responses in animal models A Conforti, E Marra, F Palombo, G Roscilli, M Ravà, V Fumagalli, A Muzi, ... Molecular Therapy 30 (1), 311-326, 2022 | 61 | 2022 |
| Weak correlation between antibody titers and neutralizing activity in sera from SARS‐CoV‐2 infected subjects E Criscuolo, RA Diotti, M Strollo, S Rolla, A Ambrosi, M Locatelli, ... Journal of medical virology 93 (4), 2160-2167, 2021 | 54* | 2021 |
| Unconventional CD147‐dependent platelet activation elicited by SARS‐CoV‐2 in COVID‐19 N Maugeri, R De Lorenzo, N Clementi, RA Diotti, E Criscuolo, C Godino, ... Journal of Thrombosis and Haemostasis 20 (2), 434-448, 2022 | 51 | 2022 |
| Peptide‐based vaccinology: experimental and computational approaches to target hypervariable viruses through the fine characterization of protective epitopes recognized by … M Castelli, F Cappelletti, RA Diotti, G Sautto, E Criscuolo, M Dal Peraro, ... Journal of Immunology Research 2013 (1), 521231, 2013 | 40 | 2013 |
| Neutralization interfering antibodies: a “novel” example of humoral immune dysfunction facilitating viral escape? M Nicasio, G Sautto, N Clementi, RA Diotti, E Criscuolo, M Castelli, ... Viruses 4 (9), 1731-1752, 2012 | 30 | 2012 |
| Harmonization of six quantitative SARS-CoV-2 serological assays using sera of vaccinated subjects D Ferrari, N Clementi, SM Spanò, S Albitar-Nehme, S Ranno, ... Clinica Chimica Acta 522, 144-151, 2021 | 29 | 2021 |
| Antibody titer kinetics and SARS-CoV-2 infections six months after administration with the BNT162b2 vaccine D Ferrari, N Clementi, E Criscuolo, A Ambrosi, F Corea, C Di Resta, ... Vaccines 9 (11), 1357, 2021 | 28 | 2021 |
| JC polyomavirus (JCV) and monoclonal antibodies: friends or potential foes? RA Diotti, A Nakanishi, N Clementi, N Mancini, E Criscuolo, L Solforosi, ... Journal of Immunology Research 2013 (1), 967581, 2013 | 27 | 2013 |
| Broad-range neutralizing anti-influenza A human monoclonal antibodies: new perspectives in therapy and prophylaxis. N Clementi, E Criscuolo, M Castelli, M Clementi Microbiologica-Quarterly Journal of Microbiological Sciences 35 (4), 399, 2012 | 26 | 2012 |
| Combined Prophylactic and Therapeutic Use Maximizes Hydroxychloroquine Anti-SARS-CoV-2 Effects in vitro N Clementi, E Criscuolo, RA Diotti, R Ferrarese, M Castelli, L Dagna, ... Frontiers in microbiology 11, 1704, 2020 | 20 | 2020 |
| Cell-to-cell spread blocking activity is extremely limited in the sera of herpes simplex virus 1 (HSV-1)-and HSV-2-infected subjects E Criscuolo, M Castelli, RA Diotti, V Amato, R Burioni, M Clementi, ... Journal of Virology 93 (11), 10.1128/jvi. 00070-19, 2019 | 20 | 2019 |
Nicola ClementiAssociate Professor at Vita-Salute San Raffaele University在 hsr.it 的电子邮件经过验证
